文献リスト

1）Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44

2）Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res. 2013; 43(1): 1-34

3）McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360: 1827-38

4）Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360: 1839-50

5）McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362: 1292-303

6）Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16

7）Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365: 1014-24

8）Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-28

9）Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56: 78-84

10）Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012; 19: 134-42

11）Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011; 141: 881-9

12）Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376: 705-16

13）Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1195-206

14）Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207-17

15）Fried M, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. In press

16）Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. In press

17）Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. In press

18）Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, A phase III trial. J Hepatol. 2013; 58(Suppl.1): S574

19）Manns M, Marcellin P, Fred FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, A phase III trial. J Hepatol. 2013; 58(Suppl.1): S568

20）Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Results from PROMISE, a phase III trial. Gastroeterology 2013; 144(Suppl.1): S-151

21）林　紀夫，他．ゲノタイプ1型C型肝炎に対するシメプレビル(TMC435)併用療法(CONCERTO-1試験)の有効性の検討．肝臓．2013; 54（Suppl. 1）: A24

22）泉　並木，林　紀夫，他．ゲノタイプ1型C型肝炎に対するシメプレビル（TMC435）による再治療の有効性の検討（CONCERTO-2/3試験）．肝臓．2013; 54（Suppl. 1）: A156

23）鈴木文孝，林　紀夫，他．ゲノタイプ1型C型肝炎に対するシメプレビル（TMC435）のペグインターフェロンα-2b及びリバビリン併用療法（CONCERTO-4試験）．肝臓．2013; 54（Suppl. 1）: A157

24）Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012; 56: 1247-53

25）Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study. Hepatology. 2012; 56: 884-93

26）Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol. 2013; 59: 11-7

27）Izumi N, Asahina Y, Yokosuka O, et al. Combination therapy of treatment-naïve and nonresponder patients with HCV genotype 1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin. Hepatology. 2011; 54(Suppl): 1439A

28）Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366: 216-24

29）McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013; 58: 902-11

30）Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012; 55: 742-8

31）Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013; 58: 655-62

32）Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013; 58: 646-54

33）Chayama K, Suzuki Y, Ikeda K, et al. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naïve/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. Hepatology 2013; 58(Suppl): 313A

34）Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011; 141: 2047-55

35）Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9

36）Zeuzem S, Dufour JF, Buti M, et al. Interferon-free treatment with faldaprevir, BI207127 and ribavirin in SOUND-C3: 95% SVR12 in HCV-GT1b. Hepatol Int. 2013; 7(Suppl 1): S445

37）Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381: 2100-7

38）Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13: 401-8

39）Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368: 34-44

40）Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 1867-77

41）Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-87

42）Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotype 1, 2, and 3: The ELECTRON trial. Hepatology. 2012; 56(Suppl): 306A

43）Gane EJ, Stedman CA, Hyland RH, et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol. 2013; 58(Suppl.1): S6

44）Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir/ledipasvir fixes dose combination with or without ribavirin: the ELECTRON trial. Hepatology 2013; 58(Suppl): 243A

45）Lawitz E, Poordad F, Hyland RH, et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in ≥ 95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial. Hepatology 2013; 58(Suppl): 315A

46）Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection. J Hepatol. In press

47）Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− ribavirin in patients with chronic HCV GT1 infection: Results from the AVIATOR study. J Hepatol. 2013; 58(Suppl.1): S2

48）Lawitz W, Hezode C, Varunok P, et al. Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naive patients and prior null responders. Hepatology 2013; 58(Suppl): 244A

49）Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013; 59: 205-12

50）Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013; 59: 434-41

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp